Advertisement
CRSP vs MRNA
Which Stock Would AI Choose? CRISPR Therapeutics (CRSP) vs. Moderna (MRNA) Stock Comparison
Key Takeaways
- CRSP is a pioneer in CRISPR/Cas9 gene editing with its approved therapy Casgevy, but it remains pre-profit and range-bound in recent market activity.
- MRNA has delivered one of the strongest biotechnology rallies of the year, driven by positive Phase 3 cancer-vaccine data, but the move has been highly volatile and leaves the shares well above average analyst targets.
- Both companies are unprofitable and rely heavily on future pipeline milestones, making their relative performance more about catalysts and sentiment than current earnings.
- Tickeron AI Verdict: On balance, the AI framework currently favors MRNA for its stronger momentum and catalyst-rich pipeline, while acknowledging its elevated volatility and valuation risk.
- For more context on each name, explore CRSP Major News and CRSP Today's Price Move, as well as MRNA Major News and MRNA Today's Price Move.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Introduction
CRISPR Therapeutics (CRSP) and Moderna (MRNA) are two of the most closely watched names in biotechnology, yet they represent very different stages of commercial maturity and very different recent price behavior. CRISPR is an early-commercialization gene-editing company whose flagship therapy is just beginning to generate revenue, while Moderna is a scaled messenger RNA (mRNA) platform developer transitioning beyond COVID-19 vaccines into oncology. Investors comparing these two stocks are effectively weighing a lower-valuation, catalyst-dependent story against a high-momentum, high-volatility turnaround. This stock comparison is relevant for growth-oriented traders tracking biotechnology catalysts as well as longer-horizon investors assessing relative market positioning in innovative medicine.
CRSP Overview and Recent Performance
CRISPR Therapeutics develops gene-based medicines using its CRISPR/Cas9 platform, a technology that edits DNA with precision. Its lead product, Casgevy, became the first CRISPR-based therapy approved by the U.S. Food and Drug Administration (FDA), treating sickle cell disease and transfusion-dependent beta thalassemia. In recent weeks, the stock has traded in a relatively narrow band below key short-term moving averages, reflecting a market that is still waiting for commercialization to translate into meaningful revenue. Recent developments have included a chief financial officer transition and a series of insider share sales, alongside continued accumulation by Cathie Wood's Ark Invest. Investors are also watching upcoming data readouts, including Phase 1b results for CTX310, an in vivo (inside the body) gene-editing candidate targeting the ANGPTL3 gene for cardiovascular risk. Sentiment remains divided, with analyst targets spanning a wide range as the market weighs the promise of an expanding pipeline against a business that is still burning cash.
MRNA Overview and Recent Performance
Moderna built its franchise on messenger RNA (mRNA), a molecule that instructs cells to produce proteins, and became a household name through its COVID-19 vaccine. As pandemic-era demand normalized, the company pivoted toward a broader portfolio that now includes an RSV (respiratory syncytial virus) vaccine and the first mRNA-based seasonal flu vaccine approved by the FDA for adults aged 50 and older. Recent market activity has been dominated by the personalized cancer vaccine intismeran autogene, developed with Merck. Positive Phase 3 data in high-risk melanoma showing a 42% reduction in the risk of recurrence or death versus Merck's Keytruda alone sent the shares sharply higher over recent months, though the rally has also been punctuated by steep pullbacks amid a reported data leak and analyst downgrades. The stock has risen several hundred percent over the past year, but the company remains loss-making, and the average analyst price target sits well below the current price.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of securities. Because no single approach suits every market regime, only a curated subset earns a place in the Trending AI Robots section. This selection highlights the bots best suited to current market conditions, spanning strategies from short-term momentum to swing trading and longer-horizon positioning. The bots vary widely in win rate, trade frequency, and risk profile, giving users a view into how systematic, rules-based strategies are navigating volatility. For investors comparing names like CRISPR Therapeutics and Moderna, observing which algorithms are actively trading these tickers can offer a data-driven counterpoint to headline-driven sentiment. Explore the Trending AI Robots page to review current performance and strategy details.
Head-to-Head Comparison
The two companies diverge sharply on business model and growth drivers. CRSP is effectively a one-product commercial story in its early days, dependent on the gradual patient uptake of Casgevy and on pipeline candidates such as its off-the-shelf CAR-T (chimeric antigen receptor T-cell) therapies and cardiovascular programs. Its market capitalization is modest relative to its peers, and its revenue is still small. MRNA, by contrast, has multiple approved products and a larger revenue base, though that revenue has been shrinking and the company remains deeply unprofitable. In terms of momentum, Moderna's recent rally is far stronger than CRISPR's sideways consolidation, but that momentum has come with outsized single-session swings and a valuation that many analysts consider stretched. Risk profiles also differ: CRISPR's risk is concentrated in clinical and commercial execution for a handful of programs, while Moderna's risk is split between competitive respiratory-vaccine markets and the complex, patient-specific manufacturing its cancer vaccine will require. Sector exposure is similar in that both are innovation-driven biotechs, but their sentiment drivers and risk-reward profiles are meaningfully different.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and the presence of near-term catalysts, Tickeron's AI framework would likely lean toward MRNA in the current environment. Moderna has demonstrated a stronger directional trend and a more clearly defined catalyst path around its oncology program, even though that momentum has been interrupted by sharp corrections. CRISPR Therapeutics offers greater relative stability and a lower valuation, but its trend has been weaker and its catalysts are earlier stage. A trend-following, momentum-aware system would therefore assign higher probability to Moderna in the near term, while recognizing that its elevated volatility and the gap between price and analyst targets represent meaningful downside risk. This assessment reflects probabilistic positioning rather than a definitive prediction, and it is not intended as personal investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and MRNA is a Hold.
CRSP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CRSP turned positive on October 28, 2026. Looking at past instances where CRSP's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 59 cases where CRSP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 81 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
CRSP broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.768) is normal, around the industry mean (3.104). P/E Ratio (-10.614) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CRSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRNA's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for MRNA moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 24 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 72 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 62 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +7.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 215 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 94 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.040) is normal, around the industry mean (3.104). P/E Ratio (-27.673) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRSP | MRNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 34 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 97 | |
PRICE GROWTH RATING 1..100 | 58 | 1 | |
P/E GROWTH RATING 1..100 | 54 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRNA's Valuation (12) in the Biotechnology industry is in the same range as CRSP (23). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.
MRNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.
CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as MRNA (97). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's Price Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for CRSP (58). This means that MRNA’s stock grew somewhat faster than CRSP’s over the last 12 months.
CRSP's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for MRNA (99). This means that CRSP’s stock grew somewhat faster than MRNA’s over the last 12 months.
| CRSP | MRNA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 73% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| Advances ODDS (%) | 5 days ago 82% | 5 days ago 78% |
| Declines ODDS (%) | 1 day ago 81% | 1 day ago 87% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while MRNA’s FA Score has 2 green FA rating(s).
- CRSP’s FA Score: 1 green, 4 red.
- MRNA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 2 TA indicator(s) are bullish while MRNA’s TA Score has 3 bullish TA indicator(s).
- CRSP’s TA Score: 2 bullish, 7 bearish.
- MRNA’s TA Score: 3 bullish, 5 bearish.
Price Growth
CRSP (@Biotechnology) experienced а +2.00% price change this week, while MRNA (@Biotechnology) price change was +11.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.92%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -20.21%.
Reported Earning Dates
CRSP is expected to report earnings on Nov 09, 2026.
MRNA is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (-0.92% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement